Table 4 The levels of Ca, P, and iPTH in different-gender groups.
From: The current status of chronic kidney disease-mineral and bone disorder management in China
All patients (n = 7053) | Male (n = 4356) | Female (n = 2960) | P | |
|---|---|---|---|---|
Corrected Ca patients, n | 5583 | 3329 | 2254 | |
Corrected Ca (mmol/L) | 2.21 (2.05, 2.37) | 2.19 (2.03, 2.34) | 2.24 (2.08, 2.40) | < 0.001 |
Corrected Ca, n (%) | ||||
< 2.1 | 1747 (31.3) | 1131 (34.0) | 616 (27.3) | < 0.001 |
2.1–2.5 | 3214 (57.6) | 1898 (57.0) | 1316 (58.4) | 0.309 |
> 2.5 | 622 (11.1) | 300 (9.0) | 322 (14.3) | < 0.001 |
P patients, n | 6413 | 3806 | 2607 | |
P (mmol/L) | 1.78 (1.40, 2.18) | 1.79 (1.41, 2.21) | 1.75 (1.37, 2.14) | 0.003 |
P, n (%) | ||||
< 0.87 | 260 (4.1) | 150 (3.9) | 110 (4.2) | 0.579 |
0.87–1.45 | 1561 (24.3) | 901 (23.7) | 660 (25.3) | 0.132 |
1.46–1.78 | 1423 (22.2) | 833 (21.9) | 590 (22.6) | 0.481 |
> 1.78 | 3169 (49.4) | 1922 (50.5) | 1247 (47.8) | 0.036 |
iPTH patients, n | 5610 | 3355 | 2255 | |
iPTH (pg/mL) | 314.3 (164.0, 560.0) | 317.0 (173.0, 563.6) | 308.2 (149.7, 555.0) | 0.132 |
iPTH, n (%) | ||||
< 150 | 1249 (22.3) | 685 (20.4) | 564 (25.0) | < 0.001 |
150–300 | 1448 (25.8) | 912 (27.2) | 536 (23.8) | 0.004 |
301–600 | 1639 (29.2) | 982 (29.3) | 657 (29.1) | 0.914 |
601–800 | 439 (7.8) | 262 (7.8) | 177 (7.8) | 0.956 |
> 800 | 835 (14.9) | 514 (15.3) | 321 (14.2) | 0.263 |
